PE

Peptron, Inc.

Develops sustained-release peptide medicines for chronic & neurodegenerative disorders.

087010 | KO

Overview

Corporate Details

ISIN(s):
KR7087010005
LEI:
Country:
South Korea
Address:
대전광역시 유성구 유성대로1628번길 37-24, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Peptron, Inc., established in 1997, is a biotechnology company specializing in the development of peptide-based medicines. The company's core focus is its proprietary sustained-release (SR) drug delivery platform technology, known as SmartDepot, which enables the formulation of long-acting medications that can extend a drug's release profile from weekly to monthly intervals. Peptron's development pipeline targets treatments for various chronic, life-threatening, and neurodegenerative disorders. The company is actively developing exenatide as a drug for neurodegenerative conditions, supported by an exclusive license for related NIH patents.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 101.1 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-05 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 17.8 KB
2025-08-05 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.2 KB
2025-07-28 00:00
Capital/Financing Update
주요사항보고서(교환사채권발행결정)
Korean 42.6 KB
2025-07-28 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 37.0 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-04-18 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획자진취하등) (PND3174의 제1a상 임상시험계획 자진취하)
Korean 10.6 KB
2025-03-31 00:00
Post-Annual General Meeting Information
[기재정정]정기주주총회결과
Korean 29.4 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 26.0 KB
2025-03-28 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.4 KB
2025-03-28 00:00
Board/Management Information
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.2 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 17.7 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 473.5 KB
2025-03-19 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 18.6 KB

Automate Your Workflow. Get a real-time feed of all Peptron, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Peptron, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Peptron, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX
MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America
MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden
MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany
MYNZ
MANNKIND CORP Logo
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America
MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Logo
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America
MRVI
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria
MARI
Marker Therapeutics, Inc. Logo
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America
MRKR
Matinas BioPharma Holdings, Inc. Logo
Developing oral drugs via a lipid nano-crystal platform for infections, oncology & inflammation.
United States of America
MTNB
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel
MTLF

Talk to a Data Expert

Have a question? We'll get back to you promptly.